How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Related reading
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
US health agency reapproves GSK blood cancer drug after new trial
FDA gives go-ahead to UK drugmaker’s multiple myeloma treatment Blenrep
GSK blood cancer drug reapproved by EU regulator
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year